196 related articles for article (PubMed ID: 25595901)
1. Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.
Fujita Y; Yagishita S; Takeshita F; Yamamoto Y; Kuwano K; Ochiya T
Oncotarget; 2015 Feb; 6(5):3335-45. PubMed ID: 25595901
[TBL] [Abstract][Full Text] [Related]
2. Ribophorin II promotes cell proliferation, migration, and invasion in esophageal cancer cells
Li Y; Huang C; Bai Q; Yu J
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30940778
[TBL] [Abstract][Full Text] [Related]
3. RPN2 gene confers docetaxel resistance in breast cancer.
Honma K; Iwao-Koizumi K; Takeshita F; Yamamoto Y; Yoshida T; Nishio K; Nagahara S; Kato K; Ochiya T
Nat Med; 2008 Sep; 14(9):939-48. PubMed ID: 18724378
[TBL] [Abstract][Full Text] [Related]
4. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of RPN2 induces apoptosis and inhibits migration and invasion in colon carcinoma.
Bi C; Jiang B
Oncol Rep; 2018 Jul; 40(1):283-293. PubMed ID: 29749494
[TBL] [Abstract][Full Text] [Related]
6. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA‑422a functions as a tumor suppressor in glioma by regulating the Wnt/β‑catenin signaling pathway via RPN2.
Sun J; Chen Z; Xiong J; Wang Q; Tang F; Zhang X; Mo L; Wang C; Fan W; Wang J
Oncol Rep; 2020 Nov; 44(5):2108-2120. PubMed ID: 33000268
[TBL] [Abstract][Full Text] [Related]
8. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
10. RPN2 Gene Confers Osteosarcoma Cell Malignant Phenotypes and Determines Clinical Prognosis.
Fujiwara T; Takahashi RU; Kosaka N; Nezu Y; Kawai A; Ozaki T; Ochiya T
Mol Ther Nucleic Acids; 2014 Sep; 3(9):e189. PubMed ID: 25181275
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of RPN2 suppresses radiosensitivity of glioma cells by activating STAT3 signal transduction.
Li C; Ran H; Song S; Liu W; Zou W; Jiang B; Zhao H; Shao B
Mol Med; 2020 May; 26(1):43. PubMed ID: 32404045
[TBL] [Abstract][Full Text] [Related]
12. CircNFIX promotes progression of glioma through regulating miR-378e/RPN2 axis.
Ding C; Wu Z; You H; Ge H; Zheng S; Lin Y; Wu X; Lin Z; Kang D
J Exp Clin Cancer Res; 2019 Dec; 38(1):506. PubMed ID: 31888753
[TBL] [Abstract][Full Text] [Related]
13. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
14. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
Zhang Z; Zhang L; Yin ZY; Fan XL; Hu B; Wang LQ; Zhang D
Int J Clin Exp Pathol; 2014; 7(10):7236-41. PubMed ID: 25400821
[TBL] [Abstract][Full Text] [Related]
15. Synaptic acetylcholinesterase targeted by microRNA-212 functions as a tumor suppressor in non-small cell lung cancer.
Lu L; Zhang X; Zhang B; Wu J; Zhang X
Int J Biochem Cell Biol; 2013 Nov; 45(11):2530-40. PubMed ID: 23974008
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of ribophorin II is required for viability of nasopharyngeal cancer cells by regulating JAK1/STAT3 activation.
Wang B; Liu W; Jiang X; Li J; Hu X; Li L; Gu Q
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):471-477. PubMed ID: 34184962
[TBL] [Abstract][Full Text] [Related]
17. A novel platform to enable inhaled naked RNAi medicine for lung cancer.
Fujita Y; Takeshita F; Mizutani T; Ohgi T; Kuwano K; Ochiya T
Sci Rep; 2013 Nov; 3():3325. PubMed ID: 24270189
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.
Yang YR; Zang SZ; Zhong CL; Li YX; Zhao SS; Feng XJ
Int J Clin Exp Pathol; 2014; 7(10):6929-35. PubMed ID: 25400777
[TBL] [Abstract][Full Text] [Related]
19. RPN2 in cancer: An overview.
Han Z; Wang Y; Han L; Yang C
Gene; 2023 Mar; 857():147168. PubMed ID: 36621657
[TBL] [Abstract][Full Text] [Related]
20. The expression and clinical significance of ribophorin II (RPN2) in human breast cancer.
Ono M; Tsuda H; Kobayashi T; Takeshita F; Takahashi RU; Tamura K; Akashi-Tanaka S; Moriya T; Yamasaki T; Kinoshita T; Yamamoto J; Fujiwara Y; Ochiya T
Pathol Int; 2015 Jun; 65(6):301-8. PubMed ID: 25881688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
